ArticlePharmaceutical research2014
Self-assembled chitosan-ceramide nanoparticle for enhanced oral delivery of paclitaxel.
Article in Pharmaceutical research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 31 citations in OpenAlex.
- Development of Multifunctional Targeted Dual-Loaded Polymeric Nanoparticles for Triple-Negative Breast Cancer Treatment.Pharmaceutics · 2025Article
- Exploring the potential of polymers: advancements in oral nanocarrier technology.Beilstein journal of nanotechnology · 2025Review
- Advances in Chitosan-based Drug Delivery Systems in Melanoma: A Narrative Review.Current medicinal chemistry · 2024Review
- Therapeutic Potential of Ceramide in Cancer Treatment.Journal of cancer research and oncobiology · 2024Article
- The Potential of Chitosan in Nanomedicine: An Overview of the Cytotoxicity of Chitosan Based Nanoparticles.Frontiers in pharmacology · 2022Review
- Quality by design (QbD) approach in processing polymeric nanoparticles loading anticancer drugs by high pressure homogenizer.Heliyon · 2020Review
- Article
- Cell-penetrating peptides and their analogues as novel nanocarriers for drug delivery.BioImpacts : BI · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
pusposeWe aimed to synthesize novel ceramide-chitosan (CS-CE) conjugate that forms stable polymeric nanoparticle capable of functioning as efficient carriers of hydrophobic drug such as Paclitaxel (PTX) for oral delivery.
methodsChitosan (3-5 kDa) was conjugated with ceramide by using a DSC coupling reagent to improve its hydrophobic drug entrapment capacity. The structure of the conjugate was determined by proton ((1)H) NMR and FT-IR spectrometry. Size distribution and zeta potential were measured by DLS and PTX content in the cells and plasma was determined by HPLC and LC-MS.
resultsUnder suitable conditions, the CS-CE self assembled to form colloidally stable nanoparticles with a mean diameter of ~300 nm. Further, PTX was incorporated into the CS-CE nanoparticle with 96.9% loading efficiency and 12.1% loading capacity via an emulsion-solvent evaporation method. The PTX-loaded CS-CE (PTX-CS-CE) showed sustained release of PTX and a comparable cytotoxic efficacy to that of free PTX on B16F10 melanoma and MCF-7 human breast adenocarcinoma cell lines. The empty nanoparticles showed no toxicity, indicating that the copolymer is safe to use in drug delivery. In addition, higher cellular uptake and slightly better pharmacokinetic parameters were obtained for PTX-CS-CE nanoparticle compared to free PTX.
conclusionThe polymeric nanoparticle of CS-CE represents a promising nanocarrier of hydrophobic drug for oral delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.